Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Update on Consumer Healthcare Joint Venture with Pfizer
The transaction between GSK and Pfizer Inc to create a Consumer Healthcare Joint Venture, was approved at a General Meeting held by GSK.
-
Phase III CAPTAIN study of Trelegy Ellipta in patients with asthma meets primary endpoint
Phase III CAPTAIN study of Trelegy Ellipta in patients with asthma meets primary endpoint
-
GSK delivers sales of £7.7 billion +6% AER, +5% CER
Total EPS 16.8p, +50% AER, +42% CER; Adjusted EPS 30.1p, +22% AER, +18% CER
-
ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV
If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV.
-
ViiV Healthcare announces CHMP Positive Opinion for Dovato® (dolutegravir/lamivudine) as a once-daily, single-pill, two-drug regimen for the treatment of HIV infection
Recommendation based on GEMINI 1 & 2 studies which demonstrated non-inferior efficacy.
-
GSK receives US approval of Benlysta for intravenous use in children with lupus aged five years and above
FDA approval marks the first medicine in the US approved for children with systemic lupus erythematosus (SLE)
-
US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults
Dovato strengthens ViiV Healthcare’s industry-leading portfolio of innovative treatment approaches for people living with HIV.
-
ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks
SWORD studies demonstrate long-term durable efficacy and tolerability of Juluca for treatment of virologically suppressed adults with HIV
-
GSK publishes product sales reporting changes and the impact of IFRS 16 ‘Leases’
GSK, financial reporting under regular review to ensure that it remains current and in line with developing best practice within industry.
-
GSK announces further positive data from DREAMM-1 study of anti-BCMA antibody-drug conjugate in patients with relapsed/refractory multiple myeloma
Median progression-free survival extends to twelve months.
-
Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer
TESARO announced the presentation of data from the Phase 1/2 GARNET study
-
ViiV Healthcare presents positive, 48-week data from two pivotal phase III studies showing long-acting, injectable two-drug regimen of cabotegravir and rilpivirine has similar efficacy to daily, three-drug oral treatment in adults living with HIV-1 infection
Comprehensive data from ATLAS and FLAIR studies presented today at the 2019 Conference on Retroviruses and Opportunistic Infections
-
GSK receives a positive CHMP opinion for intravenous zanamivir for the treatment of complicated influenza
Positive opinion by CHMP for intravenous zanamivir for the treatment of complicated and potentially life-threatening influenza A or B virus
-
GSK delivers sales, earnings and cash flow growth in 2018
Total EPS 73.7p, +>100% AER, +>100% CER; Adjusted EPS 119.4p +7% AER, +12% CER
-
GSK and Merck KGaA, Darmstadt, Germany announce global alliance to jointly develop and commercialise M7824, a novel immunotherapy with potential in multiple difficult-to-treat cancers
GlaxoSmithKline plc (LSE/NYSE: GSK) and Merck KGaA, Darmstadt, Germany announced that they have entered into a global strategic alliance
-
GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has successfully completed the acquisition of TESARO, Inc.
-
GSK announces succession plan to appoint new Chairman
GSK announces that Sir Philip Hampton has informed the Board of his intention to step down as non-executive Chairman.
-
Two positive phase III studies of tafenoquine for the radical cure of Plasmodium vivax malaria published in The New England Journal of Medicine
GSK and Medicines for Malaria Venture announced the publication of positive results from two phase III studies of single-dose tafenoquine
-
GlaxoSmithKline plc and Pfizer Inc to form new world-leading Consumer Healthcare Joint Venture
GSK plc has reached agreement with Pfizer Inc to combine their consumer health businesses into a new world-leading Joint Venture.
-
GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
GSK & TSRO announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO.
